Clinical trial
Phase II A Trial of Curcumin Among Patients With Prevalent Subclinical…
NCT00365209 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00365209 |
|---|---|
| Title | Phase II A Trial of Curcumin Among Patients With Prevalent Subclinical Neoplastic Lesions (Aberrant Crypt Foci) |
| Official title | Phase IIA Trial of Curcumin Among Patients With Prevalent Subclinical Neoplastic Lesions (Aberrant Crypt Foci) |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Healthy, no Evidence of Disease, Tobacco Use Disorder |
| Intervention type | Drug, Other |
| Interventions | laboratory biomarker analysis, pharmacological study, curcumin |
| Enrollment | 44 |
| Start date | Oct 1, 2006 |
| Primary completion | Sep 1, 2008 |
| Completion | Jan 1, 2011 |
| First posted | Aug 17, 2006 |
| Last update posted | Aug 27, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: